Evidence method
Level · gp.fundamentals.debt_to_revenue
173.54% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ETON · Mar 31, 2025
Eton Pharmaceuticals, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001437749-25-016475General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.00% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
12.09% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Yoy · gp.fundamentals.revenue
116.95% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
78.82% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
57.06% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-2.72% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
6.72% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
6.94% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History11 statesHistory building
Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/7 normalizedLevel 3Dec 31, 20240/9 normalizedLevel 3Mar 31, 20250/9 normalizedLevel 3Jun 30, 20250/8 normalizedLevel 3Sep 30, 20250/8 normalizedLevel 3Dec 31, 20257/9 normalizedLevel 3Mar 31, 20267/8 normalizedLevel 3Jun 30, 20267/8 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 76.42%
- Current
- 173.54%
- Delta
- 97.13%
- Previous
- 0.07%
- Current
- 0.00%
- Delta
- -0.07%
- Previous
- 2.48%
- Current
- 12.09%
- Delta
- 9.61%
- Previous
- 23.29%
- Current
- 116.95%
- Delta
- 93.66%
- Previous
- 39.05%
- Current
- 78.82%
- Delta
- 39.77%
- Previous
- 60.01%
- Current
- 57.06%
- Delta
- -2.95%
- Previous
- -6.66%
- Current
- -2.72%
- Delta
- 3.94%
- Previous
- 8.34%
- Current
- 6.72%
- Delta
- -1.63%
- Previous
- 8.11%
- Current
- 6.94%
- Delta
- -1.17%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ETON Fundamental State →Has State · Eton Pharmaceuticals, Inc. →Transitioned To · ETON Fundamental State →Transitioned To · ETON BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · ETON CAPEX_INTENSITY_DECREASED →Transitioned To · ETON CASH_GENERATION_INCREASED →Transitioned To · ETON GROWTH_INCREASED →Transitioned To · ETON INVENTORY_PRESSURE_INCREASED →Transitioned To · ETON MARGIN_DECREASED →Transitioned To · ETON PROFITABILITY_INCREASED →Transitioned To · ETON R_AND_D_INTENSITY_DECREASED →Transitioned To · ETON SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.